Dr. Rabia Khan
Managing Director, Discovery Sciences
Rabia has a background in immuno-genetics with a passion for bridging the worlds of science, business and technology. She completed her BSc in Biology and Economics from McGill University in Montreal, Canada and went on to complete a PhD in Genetics studying the genetics underlying the host immune response to Typhoid.
Following this, she joined Meta, an artificial intelligence company using NLP to uncover knowledge within the biomedical literature. In her role as VP Commercial Partnerships, she worked with the CEO to understand product-market fit, built products for commercial partners and was instrumental in the IAPRA partnership. Meta has since been acquired by Chan Zuckerberg BioHub.
Following Meta, she went on to a post-doctoral fellowship at the Francis Crick Institute under Dr. Frickel, where she worked on establishing cellular models for the immune response to Toxoplasma infection in induced pluripotent stem cell derived macrophages. She returned to working at the intersection of Biology and Technology and joined BenevolentAI, an AI-enabled drug discovery company, as a scientist and established a number of pre-clinical drug-discovery programmes. She worked closely with the BenevolentAI product team to define product vision based on drug-discovery needs and rose to the role of Associate Director Strategy and Planning working closely with Prof. Jackie Hunter.